美國NovaBios埃博拉核酸PCR檢測試劑盒

廣州健侖生物科技有限公司

本司長期供應埃博拉病毒檢測試劑盒，其主要品牌包括美國NovaBios、廣州創侖等CDC使用的進口產品，試劑盒的實驗方法包括膠體金方法、ELISA方法、PCR方法等。

歡迎咨詢

歡迎咨詢2042552662

埃博拉病毒IgM、IgG、ELISA檢測試劑、埃博拉快速檢測試劑盒、

埃博拉病毒核酸檢測試劑盒（熒光探針PCR）

西非工作、旅游埃博拉檢測試劑盒

美國CDC使用的埃博拉診斷試劑——美國的NovaBios

美國NovaBios 埃博拉核酸PCR檢測試劑盒

【埃博拉簡介】

埃博拉（Ebola virus）又譯作伊波拉病毒。是一種十分罕見的病毒，1976年在蘇丹南部和剛果（金）（舊稱扎伊爾）的埃博拉河地區發現它的存在后，引起醫學界的廣泛關注和重視，“埃博拉”由此而得名。是一個用來稱呼一群屬于纖維病毒科埃博拉病毒屬下數種病毒的通用術語。是一種能引起人類和靈長類動物產生埃博拉出血熱的烈性傳染病病毒，有很高的死亡率，在50%至90%之間，致死原因主要為中風、心肌梗塞、低血容量休克或多發性器官衰竭。

埃博拉出血熱（EBHF）是由一種絲狀病毒感染導致的急性出血性、動物源性傳染病。1976年，埃博拉出血熱在非洲的蘇丹和扎伊爾暴發，病死率高達50% ～ 90% 。因該病始發于扎伊爾北部的埃博拉河流，并在該區域嚴重流行，故命名為埃博拉病毒，其形態學、致病性等與馬爾堡病毒相似，但免疫原性有所區別。

【產品介紹】

該產品是世界衛生組織（WHO）*個批準用于埃博拉病毒檢測的診斷試劑卡。不需要借助其他實驗儀器設備，只需要采取幾滴血清、血漿、血液樣品，既可以檢測，并在15分鐘內就可以得知結果是否感染埃博拉病毒。該產品具有靈敏度高、操作方便、實驗時間短等特點。

美國NovaBios

埃博拉發熱
病毒簡介
埃博拉病毒（EBOV）是引起人類和靈長類動物發生埃博拉出血熱（EBHF）的烈性病毒，由此引起的出血熱是當今世界上zui致命的病毒性出血熱，已造成10次具有規模的暴發流行。埃博拉病毒*暴發就奪走了近300人的生命，2003年又在剛果（金）讓100多人命喪黃泉，2004年5月下旬蘇丹南部疫情再發，已有4人死亡，同時俄羅斯一實驗室女科學家因針刺感染而喪命，這一病毒殺手已引起WHO的高度重視。
EBOV屬絲狀病毒科絲狀病毒屬，為單股負鏈RNA，其分子量為4.2?06，根據病毒抗原不同分為4個亞型，即埃博拉－扎伊爾、埃博拉－蘇丹、埃博拉－萊斯頓及埃博拉－科特。不同亞型EBOV的毒力不同，扎伊爾亞型毒力zui強，引起人類感染且病死率zui高，蘇丹亞型次之，萊斯頓亞型僅在非人類靈長類中引起發病和死亡，尚未見引起人類致病的報告。
EBOV可以通過感染者的血液、體液、埃博拉及各種器官迅速傳播，感染潛伏期約為2-21天，感染者zui初的癥狀是突然發熱、頭痛和肌肉痛，繼之出現嘔吐、腹瀉和腎功能障礙，zui后體內外大出血，根據不同病毒亞型，病死率zui高可達90%。
快速靈敏準確地診斷EBHF是防治關鍵。由于急性期病人血清中特異性抗體水平相當低，其診斷價值遠不如抗原或核酸檢測高。為此，Towner等采用EBOV逆轉錄聚合酶聯反應（RT-PCR）檢測方法，測定了急性期病人的EBOV和病毒載量，快速診斷為蘇丹埃博拉病毒，敏感性較高。同時發現病毒載量與疾病的預后密切相關，死亡病例RNA的復制水平明顯高于生存病例。研究者還指出，監測EBOV亞型至關重要。
目前EBHF尚無有效療法，主要采用支持治療，要特別注意維持循環血容量，監測血壓，吸氧等。zui近美國科學家用1種抗血凝蛋白質對感染EBOV的獼猴進行治療并取得一定療效，但對人體的療效有待于進一步驗證。EBOV疫苗尚處于實驗階段，在靈長類動物已顯示效力，世界上*人體EBOV疫苗試驗zui近在美國進行。

美國NovaBios

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

想了解更多的NovaBios產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室

Ebola fever
Introduction to the virus
Ebola virus (EBOV) is a potent virus that causes Ebola haemorrhagic fever (EBHF) in humans and primates. The resulting haemorrhagic fever is the most deadly viral haemorrhagic fever in the world today. With the scale of the outbreak. Ebola virus on the first outbreak to take away the lives of nearly 300 people in 2003 and in the Congo (gold) so that more than 100 people were killed in the spring, in late May 2004 southern Sudan epidemic recurrence, 4 people have died, while Russia A laboratory female scientist died due to acupuncture infection, the virus killer has aroused great attention of the WHO.
EBOV is a filamentous virus filamentous virus, a single strand of negative RNA, its molecular weight of 4.2 to 06, according to the virus antigen is divided into four subtypes, namely Ebola - Zaire, Ebola - Sudan Ebola-Leicester and Ebola-Kurt. Different subtypes of EBOV virulence, Zaire subtype of the strongest virulence, causing human infection and mortality of the highest, followed by the Sudan subtype, Reston subtype only in non-human primates cause morbidity and mortality , Has not yet been reported to cause human disease.
EBOV can spread rapidly through the blood, body fluids, Ebola and various organs of the infected person. The infection period is about 2-21 days. The initial symptoms of the infection are sudden fever, headache and muscle pain, followed by vomiting, diarrhea and Renal dysfunction, and finally bleeding in vivo and in vitro, according to different virus subtypes, the highest mortality rate of up to 90%.
Rapid and sensitive diagnosis of EBHF is the key to prevention. Because the level of specific antibody in the serum of patients with acute phase is quite low, the diagnostic value is far less than that of antigen or nucleic acid. To this end, Towner et al. Used EBOV reverse transcription polymerase chain reaction (RT-PCR) detection method to determine the acute phase of patients with EBOV and viral load, rapid diagnosis of Sudan Ebola virus, the higher sensitivity. At the same time, it was found that the viral load was closely related to the prognosis of the disease, and the replication level of the death cases was significantly higher than that of the survivors. Researchers also point out that monitoring EBOV subtypes is critical.
Currently there is no effective treatment of EBHF, the main use of supportive care, to pay special attention to maintaining circulating blood volume, monitoring blood pressure, oxygen and so on. Recently, US scientists with a kind of anti-coagulation protein on EBOV infected monkeys were treated and achieved a certain effect, but the efficacy of the human body to be further verified. The EBOV vaccine is still in the experimental stage and has been shown to be effective in primates, and the world's first human EBOV vaccine trial has recently been conducted in the United States.